Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4397683 | 0.91 | HRH4 (0.59) | HRH3HRH4CYP1A2CYP2D6KCNH2 | |
| SCHEMBL4400409 | 0.89 | HRH3 (0.60) | HRH3HRH4CYP1A2CYP2D6KCNH2 | |
| SCHEMBL4396465 | 0.88 | HRH3 (0.59) | HRH3HRH4KCNH2 | |
| SCHEMBL4398473 | 0.88 | HRH4 (0.57) | HRH3HRH4KCNH2 | |
| SCHEMBL4398526 | 0.86 | HRH4 (0.59) | HRH3HRH4CYP1A2CYP2D6KCNH2 | |
| SCHEMBL4398069 | 0.80 | HRH4 (0.71) | HRH3HRH4KCNH2 | |
| SCHEMBL4401257 | 0.80 | HRH4 (0.71) | HRH3HRH4KCNH2 | |
| SCHEMBL4395574 | 0.80 | HRH4 (0.71) | HRH3HRH4KCNH2 | |
| SCHEMBL28229132 | 0.77 | NUDT1 (0.61) | HRH4CYP1A2CYP2D6PIK3CB | |
| SCHEMBL2165477 | 0.76 | HRH4 (0.67) | HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | PALAU PHARMA, S.A. (ES) | 2009-12-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | HRH4, HRH2, HRH3 | HRH3 3/4885HRH4 1/4885CYP1A2 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.